ESR1 and neoplasm: Furthermore, despite studies reporting wide ranges of ER positivity in patients, the molecular basis of endocrine responses in ‘ER‐low’ (<10% ER positivity) compared to ‘ER‐high’ tumours has not been clearly defined.7, 8, 9